Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function

Summary

The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.

Eligibility

Inclusion Criteria:

* Children aged 12 to 16 years
* Obesity. Defined as a body-mass index above the 97th percentile.
* Ability to give informed consent as documented by signature

Exclusion Criteria:

* Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8.
* Patients with known liver disease (other than NAFLD)
* Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion.
* Patients treated with a drug known to affect liver function

Conditions4

Browse More Trials